Bioequivalence assessment of topical clobetasol propionate products using visual and chromametric assessment of skin blanching

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 11, Issue 1, 2008, Pages 160-166

  Au, Wai Ling ^a   Skinner, Michael ^a   Kanfer, Isadore ^a  

^a RHODES UNIVERSITY   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

CLOBETASOL;

ADULT; ARTICLE; CHROMATOGRAPHY; COMPARATIVE STUDY; DRUG EFFECT; FEMALE; HUMAN; INTRADERMAL DRUG ADMINISTRATION; MALE; METABOLISM; METHODOLOGY; PATCH TEST; PHARMACOKINETICS; PHYSIOLOGY; SKIN; SKIN ABSORPTION; VISION;

ADMINISTRATION, CUTANEOUS; ADULT; CHROMATOGRAPHY; CLOBETASOL; FEMALE; HUMANS; MALE; PATCH TESTS; SKIN; SKIN ABSORPTION; THERAPEUTIC EQUIVALENCY; VISION;

EID: 53549115634     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/j3np48     Document Type: Article

References (28)

1. K. A. Horii, S. D. Simon, D. Y. Liu and V. Sharma. Atopic dermatitis in children in the United States, 1997-2004: visit trends, patient and provider characteristics, and prescribing patterns. Paed, 120:e527-e534, 2007.
2. T. Afifi, G. de Gannes, C. Huang and Y. Zhou. Topical therapies for psoriasis: evidence-based review. Can Fam Physician, 51:519-525, 2005.
3. A. Ahluwalia. Topical glucocorticosteroids and the skin-mechanisms of action: an update. Mediat Inflamm, 7:183-193, 1998.
4. H. Baker H. A. Sattar. The assessment of four new fluocortolone analogues bu a modified vasoconstriction assay. Br J Derm, 80:46-53, 1968.
5. Guidance: Topical dermatological corticosteroids: In vivo bioequivalence, division of bioequivalence, office of generic drugs, food and drug administration (FDA). Rockville, MD., U.S.A. 1995.
6. A. W. McKenzie and R. B. Stoughton. Method for comparing percutaneous absorption of steroids. Arch Dermatol, 86:608-610, 1962.
7. L. K. Pershing, B. S. Silver, G. G. Krueger, V. P. Shah and J. P. Skelly. Feasibility of measuring the bioavailability of topical betamethasone dipropionate in commercial formulations using drug content in skin and a blanching bioassay. Pharm Res, 9:45-51, 1992.
8. B. W. Barry and R. Woodford. Activity and bioavailability of topical corticosteroids: In vivo/in vitro correlations for the vasoconstrictor test. J Clin Pharm, 3:43-65, 1978.
9. K. H. Burdick. Corticosteroid bioavailability assays. Acta Derm-Venereol (Stockholm), 52:19-23, 1972.
10. B. W. Barry. Bioavailability of topical steroids. Dermatologica, 152:47-65, 1976.
11. G. L. Coleman, I. Kanfer and J. M. Haigh. Comparative blanching activities of proprietary diflucortolone valerate topical preparations. Dermatologica, 156:224-230, 1978.
12. E. Meyer, A. D. Magnus, J. M. Haigh and I. Kanfer. Comparison of the blanching activities of Dermovate, Betnovate and Eumovate creams and ointments. Int J Pharm, 41:63-66, 1988.
13. Smith, E. W., Meyer, E., Haigh, J. M., Maibach, H. I., The Human Skin Blanching Assay as an Indicator of Topical Corticosteroid Bioavailability and Potency: An Update in Bronaugh RL: Maibach HI (eds), Percutaneous Absorption: Mechanisms, Methodology and Drug Delivery. 2nd ed., Marcel Dekker, Inc, New York, pp 443-460, 1989.
14. J.C. Tsai, C.L. Cheng, Y.F. Tsai, H.M. Sheu and C.H. Chou. Evaluation of in vivo bioequivalence methodology for topical clobetasol 17-propionate based on pharmacodynamic modeling using Chinese skin. J Pharm Sci, 93:207-217, 2003.
15. T. Keida, N. Hayashi and M. Kawashima. Application of the Food and Drug Administration (FDA) bioequivalent guidance of topical dermatological corticosteroid in yellow-skinned Japanese population: validation study using a chromameter. J Dermatol, 10:684-691, 2006.
16. M. Bach and B.C. Lippold. Influence of penetration enhancers on the blanching intensity of betamethasone 17-benzoate. Int J Pharm, 168:97-108, 1998.
17. S.R. Feldman. Relative efficacy and interchangeability of various clobetasol propionate vehicles in the management of steroid-responsive dermatoses. Curr Ther Res, 66:154-171, 2005.
18. S. Y. Chan and A. L. W. Po. Quantitative skin blanching assay of corticosteroid creams using tristimulus colour analysis. J Pharm Pharmacol, 44:371-378, 1992.
19. P. Clarys, L. Wets, A. Barel, and B. Gabard. The skin blanching assay with halcinonide; influence of halcinonide concentration and application time. J Env Eng Div-Asce, 5: 250-257, 1995.
20. M. J. Waring, L. Monger, D. A. Hollingsbee, G. P. Martin and C. Marriot. Assessment of corticosteroid-induced skin blanching: evaluation of the Minolta Chromameter CR200. Int J Pharm, 94:211-212, 1993.
21. L. K. Pershing, L. D. Lambert, V. P. Shah and S. Y. Lam. Variability and correlation of chromameter and tape-stripping methods with the visual skin blanching assay in the quantitative assessment of topical 0.05% betamethasone dipropionate bioavailability in humans. Int J Pharm, 86:201-210, 1992.
22. P. H. Demana, E. S. Smith, R. B. Walker, J. M. Haigh and I. Kanfer. Evaluation of the proposed FDA pilot dose-response methadology for topical corticosteroid bioequivalence testing. Pharm Res, 14:303-308, 1997.
23. F. P. Schwarb, E. W. Smith, J. M. Haigh and C. Surber. Analysis of chromameter results obtained from corticosteroid-induced skin blanching assay: comparison of visual chromameter data. Eur J Pharm, 47:261-267, 1999.
24. J.M. Haigh and E.W. Smith. Topical corticosteroid-induced skin blanching measurement: eye or instrument? Letter to the editor. Arch Dermatol, 127:1065, 1991.
25. J.P. Skelly, V.P. Shah and C.C. Peck, Topical Corticosteroid-induced Skin Blanching Measurement: Eye or Instrument? Response to the editor. Arch Dermatol, 127: 1065, 1991.
26. Skin type evaluation. http://www.reflectionscenter.com/skin_type.htm.
27. J. M. Haigh, and I. Kanfer. Assessment of topical corticosteroid preparations: the human skin blanching assay-review article. Int J Pharm, 19:245-262, 1984.
28. Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products-general considerations. Center for Drug Evaluation, Food and Drug Administration (FDA), Rockville, MD., U.S.A. 2000.